nach oben

Wiener klinisches Magazin

Erschienen in:

01.06.2016 | Onkologie

Pankreaskarzinom

Risikofaktoren, Hochrisikodefinition und mögliche Screeningmaßnahmen

verfasst von: Dr. Florian Obermair, Dr. Ulrich Popper, Dr. Franz Romeder, OA Priv.-Doz. Holger Rumpold

Erschienen in: Wiener klinisches Magazin | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Pankreaskarzinom (PK) weist von allen Karzinomen des Gastrointestinaltraktes die schlechteste Prognose auf. In den letzten Jahren wurden zunehmend Faktoren identifiziert, die mit einem deutlich erhöhten PK-Risiko einhergehen. Dazu werden sowohl genetische als auch nicht genetische Risikofaktoren gezählt. Erstere umfassen einerseits gut etablierte Tumorsyndrome wie das erbliche Brust- und Eierstockkrebssyndrom (BRCA1, BRCA2, PALB2) oder das Lynch-Syndrom (MLH1, MSH2, MSH6, PMS2) aber auch seltenere Tumorsyndrome wie das Peutz-Jeghers-Syndrom (STK11) oder das familiäre multiple Melanom-Syndrom (CDKN2a). Zudem werden die hereditäre Pankreatitis (PRSS1, SPINK, CFTR, PRSS2) und die Nicht-0-Blutgruppen im ABO-System zu den erblichen Risikofaktoren gezählt. Unter den nicht genetischen Risikofaktoren finden sich zum einen lebensstilassoziierte Faktoren wie Rauchen, Adipositas oder Alkoholabusus und zum anderen internistische Erkrankungen wie Hepatitis B/C, Helicobacter-pylori-Infektion, chronische Pankreatitis oder Diabetes mellitus.

Diese Risikofaktoren sollen bestimmte Hochrisikokohorten definieren, die von Screeningmaßnahmen profitieren könnten. Trotz zahlreicher PK-Screening-Studien mit unterschiedlichen Modalitäten wie beispielsweise endoskopischer Ultraschall (EUS) oder Magnetresonanz-Cholangiopankreatikographie (MRCP) konnte bisher in keiner dieser Studien ein Überlebensvorteil gezeigt werden. Aus diesem Grund gibt es bisher keinen Konsens über die Art, den Beginn und die Intervalle eines PK-Screenings, weshalb ein solches derzeit nur im Rahmen von klinischen Studien angeboten werden soll.

Vorheriger Artikel PBC nicht übersehen

Howlader N SEER Database. http://seer.cancer.gov/data/. Zugegriffen: 13. Jan. 2015

Takaori K, Bassi C, Biankin A, Brunner TB, Cataldo I, Campbell F et al (2015) International Association of Pancreatology (IAP)/European Pancreas Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology 15(3):S113–S114CrossRef

Ahn DH, Williams TM, Goldstein DA, El-Rayes B, Bekaii-Saab T (2015) Adjuvant therapy for pancreas cancer in an era of value based cancer care. Cancer Treat Rev 42:10–17PubMedCrossRef

Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK et al (2013) Recent Progress in Pancreatic. CA Cancer J Clin 63(5):318–348PubMedPubMedCentralCrossRef

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825PubMedCrossRef

Hoff DD Von, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703CrossRef

Mocci E, Milne RL, Méndez-Villamil EY, Hopper JL, John EM, Andrulis IL et al (2013) Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol Biomarkers Prev 22(5):803–811PubMedPubMedCentralCrossRef

Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P et al (2012) The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 107(12):2005–2009PubMedPubMedCentralCrossRef

Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94(18):1365–1372PubMedCrossRef

10.

Martin ST, Matsubayashi H, Rogers CD, Philips J, Couch FJ, Brune K et al (2005) Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 24(22):3652–3656PubMedCrossRef

11.

Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365PubMedCrossRef

12.

Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R et al (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17. Cancer Res 62(13):3789–3793PubMed

13.

Slater EP, Langer P, Fendrich V, Habbe N, Chaloupka B, Matthäi E et al (2010) Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer 9(3):335–343PubMedCrossRef

14.

Schneider R, Slater EP, Sina M, Habbe N, Fendrich V, Matthäi E et al (2011) German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 10(2):323–330PubMedCrossRef

15.

Couch FJ, Johnson MR, Rabe KG, Brune K, Andrade M de, Goggins M et al (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16(2):342–346PubMedCrossRef

16.

Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM et al (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56(23):5360–5364PubMed

17.

Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95(3):214–221PubMedCrossRef

18.

Real FX, Malats N, Lesca G, Porta M, Chopin S, Lenoir GM et al (2002) Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer. Gut 50(5):653–657PubMedPubMedCentralCrossRef

19.

Lucas AL, Shakya R, Lipsyc MD, Mitchel EB, Kumar S, Hwang C et al (2013) High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res 19(13):3396–3403PubMedPubMedCentralCrossRef

20.

Lubezky N, Ben-Haim M, Lahat G, Marmor S, Solar I, Brazowski E et al (2012) Intraductal papillary mucinous neoplasm of the pancreas: associated cancers, family history, genetic predisposition? Surgery 151(1):70–75PubMedCrossRef

21.

Drew Y, Mulligan EA, Vong W‑T, Thomas HD, Kahn S, Kyle S et al (2011) Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 103(4):334–346PubMedCrossRef

22.

Andrei A‑Z, Hall A, Smith AL, Bascuñana C, Malina A, Connor A et al (2015) Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673. Cancer Lett 364(1):8–16PubMedCrossRef

23.

Waddell N, Pajic M, Patch A‑M, Chang DK, Kassahn KS, Bailey P et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518(7540):495–501PubMedPubMedCentralCrossRef

24.

Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J et al (2014) Olaparib Monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33(3):244–250PubMedCrossRef

25.

Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E et al (2011) An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 16(10):1397–1402PubMedPubMedCentralCrossRef

26.

Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J et al (2014) Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371(6):497–506PubMedPubMedCentralCrossRef

27.

Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW et al (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324(5924):217PubMedPubMedCentralCrossRef

28.

Slater E, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N et al (2010) PALB2 mutations in European familial pancreatic cancer families. Clin Genet 78(5):490–494PubMedCrossRef

29.

Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K et al (2011) PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer 10(2):225–231PubMedCrossRef

30.

Blanco A, Hoya M de la, Osorio A, Diez O, Miramar MD, Infante M et al (2013) Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases. PLoS ONE 8(7):e67538PubMedPubMedCentralCrossRef

31.

Harinck F, Kluijt I, Mil SE van, Waisfisz Q, Os TAM van, Aalfs CM et al (2012) Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. Eur J Hum Genet 20(5):577–579PubMedCrossRef

32.

Grant RC, Al-Sukhni W, Borgida AE, Holter S, Kanji ZS, McPherson T et al (2013) Exome sequencing identifies nonsegregating nonsense ATM and PALB2 variants in familial pancreatic cancer. Hum Genomics 7(1):11PubMedPubMedCentralCrossRef

33.

Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril M‑F et al (2006) High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66(20):9818–9828PubMedCrossRef

34.

Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT et al (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44(2):99–106PubMedCrossRef

35.

Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP et al (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333(15):970–974PubMedCrossRef

36.

Vasen HF, Gruis NA, Frants RR, Velden PA van der, Hille ET, Bergman W (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 87(6):809–811PubMedCrossRef

37.

Lim W, Olschwang S, Keller JJ, Westerman AM, Menko FH, Boardman LA et al (2004) Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 126(7):1788–1794PubMedCrossRef

38.

Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV et al (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119(6):1447–1453PubMedCrossRef

39.

Resta N, Pierannunzio D, Lenato GM, Stella A, Capocaccia R, Bagnulo R et al (2013) Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study. Dig Liver Dis 45(7):606–611PubMedCrossRef

40.

Klümpen H‑J, Queiroz KCS, Spek CA, Noesel CJM van, Brink HC, Leng WWJ de et al (2011) mTOR inhibitor treatment of pancreatic cancer in a patient with Peutz-Jeghers syndrome. J Clin Oncol 29(6):e150–e153PubMedCrossRef

41.

Swift M, Chase CL, Morrell D (1990) Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet 46(1):21–27PubMedCrossRef

42.

Swift M, Morrell D, Massey RB, Chase CL (1991) Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325(26):1831–1836PubMedCrossRef

43.

Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML et al (2012) ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2(1):41–46PubMedCrossRef

44.

Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP et al (2012) Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 30(9):958–964PubMedPubMedCentralCrossRef

45.

Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM et al (2009) Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302(16):1790–1795PubMedPubMedCentralCrossRef

46.

Lindor NM, Petersen GM, Spurdle AB, Thompson B, Goldgar DE, Thibodeau SN (2011) Pancreatic cancer and a novel MSH2 germline alteration. Pancreas 40(7):1138–1140PubMedPubMedCentralCrossRef

47.

Sparr JA, Bandipalliam P, Redston MS, Syngal S (2009) Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol 33(2):309–312PubMedPubMedCentralCrossRef

48.

Flanagan MR (2015) Pancreatic intraductal papillary mucinous neoplasm in a patient with Lynch syndrome. World J Gastroenterol 21(9):2820PubMedPubMedCentralCrossRef

49.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372(26):2509–2520PubMedCrossRef

50.

Rosendahl J, Bödeker H, Mössner J, Teich N (2007) Hereditary chronic pancreatitis. Orphanet J Rare Dis 2(1):1PubMedPubMedCentralCrossRef

51.

Teich N, Mössner J (2008) Hereditary chronic pancreatitis. Best Pract Res Clin Gastroenterol 22(1):115–130PubMedCrossRef

52.

Rebours V, Boutron-Ruault M‑C, Schnee M, Férec C, Maire F, Hammel P et al (2008) Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol 103(1):111–119PubMedCrossRef

53.

Rebours V, Lévy P, Ruszniewski P (2012) An overview of hereditary pancreatitis. Dig Liver Dis 44(1):8–15PubMedCrossRef

54.

Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P et al (2004) Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2(3):252–261PubMedCrossRef

55.

Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK, Perrault J et al (1997) Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 89(6):442–446PubMedCrossRef

56.

Hamoir C, Pepermans X, Piessevaux H, Jouret-Mourin A, Weynand B, Habyalimana J‑B et al (2013) Clinical and morphological characteristics of sporadic genetically determined pancreatitis as compared to idiopathic pancreatitis: higher risk of pancreatic cancer in CFTR variants. Digestion 87(4):229–239PubMedCrossRef

57.

Rebours V, Lévy P, Mosnier J‑F, Scoazec J‑Y, Soubeyrand M‑S, Fléjou J‑F et al (2010) Pathology analysis reveals that dysplastic pancreatic ductal lesions are frequent in patients with hereditary pancreatitis. Clin Gastroenterol Hepatol 8(2):206–212PubMedCrossRef

58.

Risch HA, Lu L, Wang J, Zhang W, Ni Q, Gao Y‑T et al (2013) ABO blood group and risk of pancreatic cancer: a study in Shanghai and meta-analysis. Am J Epidemiol 177(12):1326–1337PubMedPubMedCentralCrossRef

59.

Rizzato C, Campa D, Pezzilli R, Soucek P, Greenhalf W, Capurso G et al (2013) ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Oncol Rep 29(4):1637–1644PubMed

60.

Woo SM, Joo J, Lee WJ, Park S‑J, Han S‑S, Kim TH et al (2013) Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea: a case-control study. J Korean Med Sci 28(2):247–251PubMedPubMedCentralCrossRef

61.

Engin H, Bilir C, Üstün H, Gökmen A (2012) ABO blood group and risk of pancreatic cancer in a Turkish population in Western Blacksea region. Asian Pac J Cancer Prev 13(1):131–133PubMedCrossRef

62.

Rahbari NN, Bork U, Hinz U, Leo A, Kirchberg J, Koch M et al (2012) AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer 12(1):319PubMedPubMedCentralCrossRef

63.

Wang D‑S, Chen D‑L, Ren C, Wang Z‑Q, Qiu M‑Z, Luo H‑Y et al (2012) ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Int J Cancer 131(2):461–468PubMedCrossRef

64.

Ben Q, Wang K, Yuan Y, Li Z (2011) Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Int J Cancer 128(5):1179–1186PubMedCrossRef

65.

Nakao M, Matsuo K, Hosono S, Ogata S, Ito H, Watanabe M et al (2011) ABO blood group alleles and the risk of pancreatic cancer in a Japanese population. Cancer Sci 102(5):1076–1080PubMedCrossRef

66.

Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB (2010) ABO blood group and cancer. Eur J Cancer 46(18):3345–3350PubMedCrossRef

67.

Risch HA, Yu H, Lu L, Kidd MS (2010) ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study. J Natl Cancer Inst 102(7):502–505PubMedPubMedCentralCrossRef

68.

Wolpin BM, Kraft P, Xu M, Steplowski E, Olsson ML, Arslan AA et al (2010) Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium. Cancer Epidemiol Biomarkers Prev 19(12):3140–3149PubMedPubMedCentralCrossRef

69.

Wolpin BM, Chan AT, Hartge P, Chanock SJ, Kraft P, Hunter DJ et al (2009) ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 101(6):424–431PubMedPubMedCentralCrossRef

70.

Wolpin BM, Kraft P, Gross M, Helzlsouer K, Bueno-de-Mesquita HB, Steplowski E et al (2010) Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res 70(3):1015–1023PubMedPubMedCentralCrossRef

71.

Annese V, Minervini M, Gabbrielli A, Gambassi G, Manna R (1990) ABO blood groups and cancer of the pancreas. Int J Pancreatol 6(2):81–88PubMed

72.

Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA et al (2009) Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 41(9):986–990PubMedPubMedCentralCrossRef

73.

Duan Y‑F, Zhu F, Li X‑D, An Y, Zhang H, Zhou Y et al (2015) Association between ABO gene polymorphism (rs505922) and cancer risk: a meta-analysis. Tumour Biol 36(7):5081–5087PubMedCrossRef

74.

Risch HA (2012) Pancreatic cancer: Helicobacter pylori colonization, N‑nitrosamine exposures, and ABO blood group. Mol Carcinog 51(1):109–118PubMedCrossRef

75.

Fendrich V, Langer P, Bartsch DK (2014) Familial pancreatic cancer–status quo. Int J Colorectal Dis 29(2):139–145PubMedCrossRef

76.

Bartsch DK, Gress TM, Langer P (2012) Familial pancreatic cancer—current knowledge. Nat Rev Gastroenterol Hepatol 9(8):445–453. doi:10.1038/nrgastro.2012.111PubMedCrossRef

77.

Rieder H, Bartsch DK (2004) Familial pancreatic cancer. Fam Cancer 3(1):69–74PubMedCrossRef

78.

Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP (2010) Update on familial pancreatic cancer. Adv Surg 44(1):293–311PubMedPubMedCentralCrossRef

79.

Chiaro M Del, Zerbi A, Falconi M, Bertacca L, Polese M, Sartori N et al (2007) Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. Pancreatology 7(5–6):459–469PubMed

80.

Lynch HT, Lynch JF, Lanspa SJ (2010) Familial pancreatic cancer. Cancers (Basel) 2(4):1861–1883CrossRef

81.

Bartsch DK, Kress R, Sina-Frey M, Grützmann R, Gerdes B, Pilarsky C et al (2004) Prevalence of familial pancreatic cancer in Germany. Int J Cancer 110(6):902–906PubMedCrossRef

82.

Permuth-Wey J, Egan KM (2009) Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 8(2):109–117PubMedCrossRef

83.

Jacobs EJ, Chanock SJ, Fuchs CS, Lacroix A, McWilliams RR, Steplowski E et al (2010) Family history of cancer and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan). Int J Cancer 127(6):1421–1428PubMedPubMedCentralCrossRef

84.

Tersmette AC, Petersen GM, Offerhaus GJ, Falatko FC, Brune KA, Goggins M et al (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7(3):738–744PubMed

85.

Earl J, Yan L, Vitone LJ, Risk J, Kemp SJ, McFaul C et al (2006) Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 15(10):1948–1955PubMedCrossRef

86.

Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L et al (2015) Prevalence of Germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 148(3):556–564PubMedCrossRef

87.

Hu C, Hart SN, Bamlet WR, Moore RM, Nandakumar K, Eckloff BW et al (2015) Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients. Cancer Epidemiol Biomarkers Prev 25(1):207–211PubMedPubMedCentralCrossRef

88.

Steward B, Wild C. World Cancer Report 2014. International Agency for Resarch on Cancer; 2014.

89.

Duell EJ (2012) Epidemiology and potential mechanisms of tobacco smoking and heavy alcohol consumption in pancreatic cancer. Mol Carcinog 51(1):40–52PubMedCrossRef

90.

Schuller HM (2007) Nitrosamines as nicotinic receptor ligands. Life Sci 80(24–25):2274–2280PubMedPubMedCentralCrossRef

91.

Schuller HM, Tithof PK, Williams M, Plummer H 3rd (1999) The tobacco-specific carcinogen 4‑(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res 59(18):4510–4515PubMed

92.

Edderkaoui M, Hong P, Vaquero EC, Lee JK, Fischer L, Friess H et al (2005) Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5‑lipoxygenase and NADPH oxidase. Am J Physiol Gastrointest Liver Physiol 289(6):G1137–G1147PubMedCrossRef

93.

Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S et al (2009) Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer 124(1):36–45PubMedPubMedCentralCrossRef

94.

Ye X, Weinberg RA (2015) Epithelial–mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol 25(11):675–686PubMedCrossRef

95.

Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT et al (2012) Cigarette smoking and pancreatic cancer: an analysis from the international pancreatic cancer case-control consortium (Panc4). Ann Oncol 23(7):1880–1888PubMedCrossRef

96.

Maisonneuve P, Lowenfels AB (2015) Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol 44(1):186–198PubMedCrossRef

97.

Blackford A, Parmigiani G, Kensler TW, Wolfgang C, Jones S, Zhang X et al (2009) Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res 69(8):3681–3688PubMedPubMedCentralCrossRef

98.

Zou L, Zhong R, Shen N, Chen W, Zhu B, Ke J et al (2014) Non-linear dose-response relationship between cigarette smoking and pancreatic cancer risk: evidence from a meta-analysis of 42 observational studies. Eur J Cancer 50(1):193–203PubMedCrossRef

99.

Vineis P, Kogevinas M, Simonato L, Brennan P, Boffetta P (2000) Levelling-off of the risk of lung and bladder cancer in heavy smokers: an analysis based on multicentric case-control studies and a metabolic interpretation. Mutat Res 463:103–110PubMedCrossRef

100.

Carmella SG, Akerkar SA, Richie JP Jr, Hecht SS (1995) Intraindividual and Interindividual differences in metabolites of the tobacco-specific lung carcinogen 4‑(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers’ urine. Cancer Epidemiol Biomarkers Prev 4(6):635–642PubMed

101.

Arslan AA, Helzlsouer KJ, Kooperberg C, Shu X‑O, Steplowski E, Bueno-de-Mesquita HB et al (2010) Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan). Arch Intern Med 170(9):791–802PubMedPubMedCentralCrossRef

102.

Stolzenberg-Solomon RZ, Adams K, Leitzmann M, Schairer C, Michaud DS, Hollenbeck A et al (2008) Adiposity, physical activity, and pancreatic cancer in the National Institutes of Health-AARP Diet and Health Cohort. Am J Epidemiol 167(5):586–597PubMedCrossRef

103.

Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML et al (2009) Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 301(24):2553–2562PubMedPubMedCentralCrossRef

104.

Stocks T, Bjørge T, Ulmer H, Manjer J, Häggström C, Nagel G et al (2015) Metabolic risk score and cancer risk: pooled analysis of seven cohorts. Int J Epidemiol 44(4):1353–1363PubMedPubMedCentralCrossRef

105.

Jiao L, Stolzenberg-Solomon R, Zimmerman TP, Duan Z, Chen L, Kahle L et al (2015) Dietary consumption of advanced glycation end products and pancreatic cancer in the prospective NIH-AARP Diet and Health Study. Am J Clin Nutr 101(1):126–134PubMedCrossRef

106.

Mendonça FM, Rodrigues De Sousa F, Barbosa AL, Martins SC, Araújo RL, Soares R et al (2015) Metabolic syndrome and risk of cancer: which link? Metabolism 64(2):182–189PubMedCrossRef

107.

Dolcet X, Llobet D, Pallares J, Matias-Guiu X (2005) NF-kB in development and progression of human cancer. Virchows Arch 446(5):475–482PubMedCrossRef

108.

Khandekar MJ, Cohen P, Spiegelman BM (2011) Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 11(12):886–895PubMedCrossRef

109.

Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG (1999) Stat3 as an oncogene without known requirements for extracellular polypep. Cell 98(3):295–303PubMedCrossRef

110.

Howard JM, Pidgeon GP, Reynolds JV (2010) Leptin and gastro-intestinal malignancies. Obes Rev 11(12):863–874PubMedCrossRef

111.

Seccareccia E, Brodt P (2012) The role of the insulin-like growth factor-I receptor in malignancy: an update. Growth Horm IGF Res 22(6):193–199PubMedCrossRef

112.

Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915–928PubMedCrossRef

113.

Seitz HK, Stickel F (2007) Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 7(8):599–612PubMedCrossRef

114.

Criddle DN, Raraty MGT, Neoptolemos JP, Tepikin AV, Petersen OH, Sutton R (2004) Ethanol toxicity in pancreatic acinar cells: mediation by nonoxidative fatty acid metabolites. Proc Natl Acad Sci USA 101(29):10738–10743PubMedPubMedCentralCrossRef

115.

Chang M‑C, Chen C‑H, Liang J‑D, Tien Y‑W, Hsu C, Wong J‑M et al (2014) Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma. World J Gastroenterol 20(17):5060–5065PubMedPubMedCentralCrossRef

116.

Luo G, Hao N‑B, Hu C‑J, Yong X, Lü M‑H, Cheng B‑J et al (2013) HBV infection increases the risk of pancreatic cancer: a meta-analysis. Cancer Causes Control 24(3):529–537PubMedCrossRef

117.

Fiorino S, Chili E, Bacchi-Reggiani L, Masetti M, Deleonardi G, Grondona AG et al (2013) Association between hepatitis B or hepatitis C virus infection and risk of pancreatic adenocarcinoma development: a systematic review and meta-analysis. Pancreatology 13(2):147–160PubMedCrossRef

118.

Li L, Wu B, Yang L‑B, Yin G‑C, Liu J‑Y (2013) Chronic hepatitis B virus infection and risk of pancreatic cancer: a meta-analysis. Asian Pac J Cancer Prev 14(1):275–279PubMedCrossRef

119.

Xu J‑H, Fu J‑J, Wang X‑L, Zhu J‑Y, Ye X‑H, Chen S‑D (2013) Hepatitis B or C viral infection and risk of pancreatic cancer: a meta-analysis of observational studies. World J Gastroenterol 19(26):4234–4241PubMedPubMedCentralCrossRef

120.

Wang Y, Yang S, Song F, Cao S, Yin X, Xie J et al (2013) Hepatitis B virus status and the risk of pancreatic cancer: a meta-analysis. Eur J Cancer Prev 22(4):328–334PubMedCrossRef

121.

Katakura Y, Yotsuyanagi H, Hashizume K, Okuse C, Okuse N, Nishikawa K et al (2005) Pancreatic involvement in chronic viral hepatitis. World J Gastroenterol 11(23):3508–3513PubMedPubMedCentralCrossRef

122.

Oliveira LC de, Rezende PB, Ferreira AL, Freitas AA de, Carvalho AM de, Guedes CA et al (1998) Concurrent acute hepatitis and pancreatitis associated with hepatitis B virus: case report. Pancreas 16(4):559–561PubMedCrossRef

123.

Raderer M, Wrba F, Kornek G, Maca T, Koller DY, Weinlaender G et al (1998) Association between Helicobacter pylori infection and pancreatic cancer. Oncology 55(1):16–19PubMedCrossRef

124.

Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, Perez-Perez G, Taylor PR, Virtamo J et al (2001) Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst 93(12):937–941PubMedCrossRef

125.

Martel C de, Llosa AE, Friedman GD, Friedmana GD, Vogelman JH, Orentreich N et al (2008) Helicobacter pylori infection and development of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 17(5):1188–1194PubMedCrossRef

126.

Lindkvist B, Johansen D, Borgström A, Manjer J (2008) A prospective study of Helicobacter pylori in relation to the risk for pancreatic cancer. BMC Cancer 8(1):321PubMedPubMedCentralCrossRef

127.

Trikudanathan G, Philip A, Dasanu CA, Baker WL (2011) Association between Helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis. JOP 12(1):26–31PubMed

128.

Xiao M, Wang Y, Gao Y (2013) Association between Helicobacter pylori infection and pancreatic cancer development: A meta-analysis. PLoS ONE 8(9):e75559PubMedPubMedCentralCrossRef

129.

Risch HA, Lu L, Kidd MS, Wang J, Zhang W, Ni Q et al (2014) Helicobacter pylori seropositivities and risk of pancreatic carcinoma. Cancer Epidemiol Biomarkers Prev 23(1):172–178PubMedCrossRef

130.

Bulajic M, Panic N, Löhr JM (2014) Helicobacter pylori and pancreatic diseases. World J Gastrointest Pathophysiol 5(4):380–383PubMedPubMedCentralCrossRef

131.

Duell EJ, Lucenteforte E, Olson SH, Bracci PM, Li D, Risch HA et al (2012) Pancreatitis and pancreatic cancer risk: a pooled analysis in the international pancreatic cancer case-control consortium (PanC4). Ann Oncol 23(11):2964–2970PubMedPubMedCentralCrossRef

132.

Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R (2010) Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 24(3):349–358PubMedCrossRef

133.

Kolodecik T, Shugrue C, Ashat M, Thrower EC, Edderkaoui M, Czakó L (2014) Risk factors for pancreatic cancer: underlying mechanisms and potential targets. Front Physiol 4:415 doi:10.3389/fphys.2013.00415PubMedPubMedCentralCrossRef

134.

Farrow B, Evers BM (2002) Inflammation and the development of pancreatic cancer. Surg Oncol 10(4):153–169PubMedCrossRef

135.

Moscat J, Diaz-Meco MT (2012) p62: a versatile multitasker takes on cancer. Trends Biochem Sci 37(6):230–236PubMedPubMedCentralCrossRef

136.

Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21(1):11–19PubMedCrossRef

137.

Aggarwal G, Kamada P, Chari ST (2013) Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 42(2):198–201PubMedPubMedCentralCrossRef

138.

Li D (2012) Diabetes and pancreatic cancer. Mol Carcinog 51(1):64–74PubMedPubMedCentralCrossRef

139.

Everhart J, Wright D (1995) Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273(20):1605–1609PubMedCrossRef

140.

Elena JW, Steplowski E, Yu K, Hartge P, Tobias GS, Brotzman MJ et al (2013) Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control 24(1):13–25PubMedCrossRef

141.

Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92(11):2076–2083PubMedPubMedCentralCrossRef

142.

Noto H, Goto A, Tsujimoto T, Noda M (2012) Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 7(3):e33411PubMedPubMedCentralCrossRef

143.

Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16(4):1103–1123PubMedCrossRef

144.

Greer JB, Whitcomb DC (2009) Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharmacol 9(4):411–418PubMedCrossRef

145.

Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH et al (2007) Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56(10):1460–1469PubMedPubMedCentralCrossRef

146.

Castillo CF del, Jimenez R (2015) Epidemiology and risk factors for exocrine pancreatic cancer. In: Savarese D (Hrsg) UpToDate. UpToDate, Waltham, MA. Zugegriffen: 01.01.2016

147.

Egawa S, Takeda K, Fukuyama S, Motoi F, Sunamura M, Matsuno S (2004) Clinicopathological aspects of small pancreatic cancer. Pancreas 28(3):235–240PubMedCrossRef

148.

Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B et al (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114–1117

149.

Al-Sukhni W, Borgida A, Rothenmund H, Holter S, Semotiuk K, Grant R et al (2012) Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 16(4):771–783PubMedCrossRef

150.

Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley J‑W, Kamel I et al (2013) International cancer of the pancreas screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62(3):339–347PubMedCrossRef

151.

Ulrich CD (2001) Pancreatic cancer in hereditary pancreatitis: consensus guidelines for prevention, screening and treatment. Pancreatology 1(5):416–422PubMedCrossRef

152.

Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS (2006) Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev 15(9):1688–1695PubMedCrossRef

153.

Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB (1999) Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 131(4):247–255PubMedCrossRef

154.

Rulyak SJ, Brentnall TA (2001) Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology 1(5):477–485PubMedCrossRef

155.

Kimmey MB, Bronner MP, Byrd DR, Brentnall TA (2002) Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 56(4 suppl):S82–S86PubMedCrossRef

156.

Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K et al (2004) Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2(7):606–621PubMedCrossRef

157.

Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C et al (2006) Screening for Early Pancreatic Neoplasia in High-Risk Individuals: A Prospective Controlled Study. Clin Gastroenterol Hepatol 4(6):766–781PubMedCrossRef

158.

Kluijt I, Cats A, Fockens P, Nio Y, Gouma DJ, Bruno MJ (2009) Atypical familial presentation of FAMMM syndrome with a high incidence of pancreatic cancer: case finding of asymptomatic individuals by EUS surveillance. J Clin Gastroenterol 43(9):853–857PubMedCrossRef

159.

Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C et al (2009) The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 104(9):2175–2181PubMedCrossRef

160.

Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M et al (2009) Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 58(10):1410–1418PubMedCrossRef

161.

Verna EC, Hwang C, Stevens PD, Rotterdam H, Stavropoulos SN, Sy CD et al (2010) Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 16(20):5028–5037PubMedCrossRef

162.

Ludwig E, Olson SH, Bayuga S, Simon J, Schattner MA, Gerdes H et al (2011) Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 106(5):946–954PubMedPubMedCentralCrossRef

163.

Vasen HFA, Wasser M, Mil A van, Tollenaar RA, Konstantinovski M, Gruis NA et al (2011) Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140(3):850–856PubMedCrossRef

164.

Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z et al (2012) Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142(4):796–804 (quiz e14–e15)PubMedPubMedCentralCrossRef

Titel: Pankreaskarzinom
Risikofaktoren, Hochrisikodefinition und mögliche Screeningmaßnahmen
verfasst von: Dr. Florian Obermair
Dr. Ulrich Popper
Dr. Franz Romeder
OA Priv.-Doz. Holger Rumpold
Publikationsdatum: 01.06.2016
Verlag: Springer Vienna
Erschienen in: Wiener klinisches Magazin / Ausgabe 3/2016
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI: https://doi.org/10.1007/s00740-016-0107-4

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Die Beharrlichkeit des Systems

The nasal microbiome in granulomatosis with polyangiitis

Diagnostik bei renaler Osteodystrophie

Der labile Kalziumpool in Hämodialysepatienten

Suche nach der individualisierten Therapie für chronische Nierenerkrankungen. Risiko: Bluthochdruck, Diabetes & Adipositas

Chemotherapie und/oder Immuntherapie?